» Articles » PMID: 34452016

Four Simple Biomimetic Mineralization Methods to Improve the Thermostability and Immunogenicity of Virus-like Particles As a Vaccine Against Foot-and-Mouth Disease

Overview
Date 2021 Aug 28
PMID 34452016
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The need for a cold chain system during storage and transport substantially increases the cost of vaccines. Virus-like particles (VLPs) are among the best countermeasures against foot and mouth disease virus (FMDV). However, VLPs are composed of pure proteins, and thus, are susceptible to heat. To address this problem, four simple biomimetic mineralization methods with the use of calcium phosphate were developed to improve heat tolerance via biomineralization. The results showed that biomineralization can significantly improve the heat resistance of VLPs. The biomineralized VLPs can be stored at low as 25 °C for eight days, and 37 °C for four days. Animal experiments showed that biomineralization had no effect on the immunogenicity of VLPs or the expression of specific antibodies (Abs) and neutralizing Abs. Even after heat treatment at 37 °C for four days, the biomineralized VLPs remained immunogenic and produced highly specific and neutralizing Abs with a high rate of protection. These results suggest that these biomineralization approaches can promote the thermal stability of VLPs against and significantly reduce dependence on cold storage and delivery systems.

Citing Articles

Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.

Ren M, Abdullah S, Pei C, Guo H, Sun S Vet Res. 2024; 55(1):128.

PMID: 39350170 PMC: 11443892. DOI: 10.1186/s13567-024-01383-x.


Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines.

Williamson G, Bachelder E, Ainslie K Mol Pharm. 2024; 21(3):1015-1026.

PMID: 38288698 PMC: 11607726. DOI: 10.1021/acs.molpharmaceut.3c00844.


Mineralization Reduces the Toxicity and Improves Stability and Protective Immune Response Induced by .

Li L, Guan Y, Bai S, Jin Q, Tao J, Zhu G Vaccines (Basel). 2024; 12(1).

PMID: 38250848 PMC: 10819335. DOI: 10.3390/vaccines12010035.


Engineering the ADDobody protein scaffold for generation of high-avidity ADDomer super-binders.

Buzas D, Sun H, Toelzer C, Yadav S, Borucu U, Gautam G Structure. 2024; 32(3):342-351.e6.

PMID: 38198950 PMC: 7616808. DOI: 10.1016/j.str.2023.12.010.


ADDovenom: Thermostable Protein-Based ADDomer Nanoparticles as New Therapeutics for Snakebite Envenoming.

Menzies S, Arinto-Garcia R, Amorim F, Cardoso I, Abada C, Crasset T Toxins (Basel). 2023; 15(12).

PMID: 38133177 PMC: 10747859. DOI: 10.3390/toxins15120673.


References
1.
Combes C, Rey C . Amorphous calcium phosphates: synthesis, properties and uses in biomaterials. Acta Biomater. 2010; 6(9):3362-78. DOI: 10.1016/j.actbio.2010.02.017. View

2.
George A, Veis A . Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition. Chem Rev. 2008; 108(11):4670-93. PMC: 2748976. DOI: 10.1021/cr0782729. View

3.
Rowe P, Kumagai Y, Gutierrez G, Garrett I, Blacher R, Rosen D . MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004; 34(2):303-19. PMC: 3357088. DOI: 10.1016/j.bone.2003.10.005. View

4.
Grgacic E, Anderson D . Virus-like particles: passport to immune recognition. Methods. 2006; 40(1):60-5. PMC: 7128828. DOI: 10.1016/j.ymeth.2006.07.018. View

5.
Michel M, Tiollais P . Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol (Paris). 2010; 58(4):288-95. DOI: 10.1016/j.patbio.2010.01.006. View